Skip to main content
. 2024 Aug 17;83(12):e225868. doi: 10.1136/ard-2024-225868

Table 1. Demographic and clinical characteristics of study participants.

Characteristic Active GCA (n=30) Inactive GCA (n=30) Non-disease controls (n=30)
Age (years)
 Mean±SD 70.5±9.3 70.9±9.3 70.0±7.8
 IQR (Q1, Q3) (63.7, 77.2) (64.1, 70.9) (65.3, 72.8)
Sex
 Female, n (%) 23 (76.7) 23 (76.7) 23 (76.7)
 Male, n (%) 7 (23.3) 7 (23.3) 7 (23.3)
Race
 White, n (%) 29 (96.7) 29 (96.7) 30 (100.0)
 Asian, n (%) 1 (3.3) 1 (3.3) 0 (0.0)
Smokers, n (%) 17 (56.7) 17 (56.7) 10 (33.3)
 Unknown, n 0 0 1
Body mass index
 Mean±SD 27.2±5.6 27.6±6.0 24.2±5.2
 IQR (Q1, Q3) (23.1, 31.0) (22.7, 31.1) (20.6, 27.5)
 Unknown, n 4 5 1
C reactive protein (mg/dL)
 Mean±SD 3.2±2.6 0.5±0.3 N/A
 IQR (Q1, Q3) (1.4, 3.7) (0.3, 0.8)
Disease stage in active GCA group
 Early disease course§, n (%) 24 (80)
 Disease duration (months) N/A N/A
  Mean±SD 7.6±11.9
  IQR (Q1, Q3) (0.4, 10.8)
 Flare history, n (%) 9 (27.3)
Physician global assessment
 Mean±SD 4.4±2.1 0.0±0.0 N/A
Treatment
 Prednisone, n (%) 22 (73.3) 21 (70.0) N/A
 Prednisone dose (mg/day)
  Median 10 10
  IQR (2.75–26) (8.75–10.0)
  Unknown, n 11 9
 Aspirin/clopidogrel, n (%)  19 (63.3) 17 (56.7)
 Aspirin low dose (mg/day) 325.0 325.0
 Abatacept/lefluomide/methotrexate, n (%) 5 (16.7) 9 (30.0)
 Statin, n (%) 4 (13.3) 5 (16.7)
 Oestrogen, n (%) 1 (3.3) 0 (0.0)

IQR, interquartile range.

§

Within 1 year of initial GCA diagnosis.

GCAgiant cell arteritisN/Anot applicable